Can Fite enrolls 1st patient in Phase IIb Namodenoson clinical trial
Category: #health  By Mateen Dalal  Date: 2022-02-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Can Fite enrolls 1st patient in Phase IIb Namodenoson clinical trial

Can Fite BioPharma, an advanced clinical stage biotechnology company ramping up pipeline of its proprietary small molecule drugs designed for inflammatory, cancer and liver diseases, has reportedly announced the enrollment of first patient in its Phase IIb study of Namodenoson for non-alcoholic steatohepatitis (NASH).

The Phase IIb clinical trial of its drug candidate Namodenoson is a randomized, multi-center, double-masked, placebo-centered study conducted in subjects diagnosed with biopsy-confirmed NASH.

Primary assessment stage of the study will focus on evaluating the efficacy of Namodenoson against that of placebo among 140 subjects with NASH, as standardized by a histological endpoint.

As a part of the study, eligible subjects are randomly aligned in 2:1 ratio, offered either 25 mg of Namodenoson dose orally every 12 hours or similar pattern of placebo for 36 weeks.

As of now, not a single NASH treatment has been approved by the U.S. FDA, while the increasing prevalence of the condition is estimated to drive the potential pharmaceutical market to approximately $35-$40 billion by 2025.

The U.S. National Institutes of Health highlights that incidences of NASH in the U.S. are seen among 2-5% of the American population.

Moreover, NASH is at the forefront of causative factors for liver transplant in women and the second to lead cause in both men and women in the U.S., notably to flag itself as the leading position in causes for liver transplants in men as well.

Dr. Pnina Fishman, CEO of Can-Fite, explained that the Phase IIa study rendered promising results associated with key liver fibrosis and NASH biomarkers and hence the biopharma anticipates similar therapeutic effect among a larger cohort of subjects tested using liver biopsy.

Currently, Can-Fite has already secured out-licensing agreements for its proprietary drug Namodenoson in the treatment of NASH in China, Eastern Europe, and South Korea, consisting of milestone payments structure along with double-digit royalties following approval and commercialization.  

Source Credit: https://www.businesswire.com/news/home/20220131005278/en/Can-Fite-Announces-First-Patient-Enrolled-in-Phase-IIb-NASH-Clinical-Trial-with-Namodenoson

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...